TY - JOUR
T1 - Yttrium-90 (90Y) in the principal radionuclide therapies
T2 - An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)
AU - Goffredo, Veronica
AU - Paradiso, Angelo
AU - Ranieri, Girolamo
AU - Gadaleta, Cosmo Damiano
PY - 2011/12
Y1 - 2011/12
N2 - The clinical application of the pure beta emitter 90Y constitutes a fundamental advancement in non-invasive medicine. Nowadays, mainly three oncological therapies exploit the intrinsic emissive characteristic of 90Y. Radionuclide therapies include peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) treatment, radioimmunotherapy (RIT) in non-Hodgkin's lymphoma (NHL) treatment and transarterial radioembolization therapy (TARET) in unresectable hepatocellular carcinoma (HCC) and liver metastatic colorectal cancer (mCRC) treatment. The last ten years of clinical experience from E-PubMed research have been reviewed and an efficacy correlation between 90Y-therapies has shown a better objective response rate for RIT (ORR 80±15%; range 53-100) compared to PRRT (ORR 23.5±14%; range 9-50), and TARET (ORR for mCRC, 40±25%; range 19-91, and ORR for HCC, 42±20%; range 20-82). This review reports on the state of the art of the efficacy of 90Y-therapies from the last decade and discusses new perspectives of therapeutic development.
AB - The clinical application of the pure beta emitter 90Y constitutes a fundamental advancement in non-invasive medicine. Nowadays, mainly three oncological therapies exploit the intrinsic emissive characteristic of 90Y. Radionuclide therapies include peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) treatment, radioimmunotherapy (RIT) in non-Hodgkin's lymphoma (NHL) treatment and transarterial radioembolization therapy (TARET) in unresectable hepatocellular carcinoma (HCC) and liver metastatic colorectal cancer (mCRC) treatment. The last ten years of clinical experience from E-PubMed research have been reviewed and an efficacy correlation between 90Y-therapies has shown a better objective response rate for RIT (ORR 80±15%; range 53-100) compared to PRRT (ORR 23.5±14%; range 9-50), and TARET (ORR for mCRC, 40±25%; range 19-91, and ORR for HCC, 42±20%; range 20-82). This review reports on the state of the art of the efficacy of 90Y-therapies from the last decade and discusses new perspectives of therapeutic development.
KW - Y-ibritumomab tiuxetan
KW - DOTATOC
KW - Microspheres
KW - Neuroendocrine tumours
KW - Non-Hodgkin's lymphoma
KW - Radioembolization
KW - Radionuclide therapy
KW - Yttrium-90
UR - http://www.scopus.com/inward/record.url?scp=80655144474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80655144474&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2011.01.012
DO - 10.1016/j.critrevonc.2011.01.012
M3 - Article
C2 - 21388824
AN - SCOPUS:80655144474
VL - 80
SP - 393
EP - 410
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 3
ER -